Abstract
In type 2 diabetic patients, insulin detemir (B29Lys(ε-tetradecanoyl),desB30 human insulin) induces less weight gain than NPH insulin. Due to the proposed reduction of tubular action by insulin detemir, type 2 diabetic patients should have increased urinary sodium excretion, thereby reducing extracellular volume and body weight when changed from NPH insulin to insulin detemir.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Diabetologia |
Vol/bind | 55 |
Udgave nummer | 1 |
Sider (fra-til) | 46-50 |
Antal sider | 5 |
ISSN | 0012-186X |
DOI | |
Status | Udgivet - 2012 |